The management of severe eosinophilic asthma, a subtype of asthma characterized by high levels of eosinophils that can cause inflammation in the airways, continues to be a challenge for healthcare providers. However, recent research points to promising advancements in treatment strategies for this specific patient group, specifically regarding the reduction of daily maintenance inhaled corticosteroids in patients treated with benralizumab.
Table of Contents
The SHAMAL Study
The SHAMAL study, a randomized, multicentre, open-label, phase 4 trial, investigated the potential of reducing the dosage of inhaled corticosteroids in patients with severe eosinophilic asthma who are being treated with benralizumab. This study’s findings carry significant implications for the management of severe eosinophilic asthma, providing valuable insights into new treatment strategies.
Results from the SHAMAL Study
According to the findings of the study, patients treated with benralizumab were able to significantly reduce their daily maintenance inhaled corticosteroid dose while maintaining control over their asthma. This is a major breakthrough, as it can reduce the side effects associated with prolonged steroid use, such as osteoporosis, diabetes, and hypertension, while maintaining disease control.
Real-world Safety and Effectiveness of Benralizumab
Further supporting the use of benralizumab in the treatment of severe eosinophilic asthma, a real-world study conducted in Japan evaluated the safety and effectiveness of benralizumab among patients with severe uncontrolled asthma. The results of this study corroborated the safety and effectiveness profiles established in randomized controlled trials, with no new safety concerns raised.
A total of 632 patients were evaluated for safety, and 274 for effectiveness. Adverse Drug Reactions (ADRs) were reported in 12.7% of patients and serious Adverse Events (AEs) in 13.0% of patients. The use of benralizumab improved the mean Asthma Control Questionnaire (ACQ-5) score by 1.16 from baseline. The annual asthma exacerbation rate was reduced to 0.42, signaling a significant reduction in the frequency of severe asthma attacks. A greater ACQ-5 score improvement was observed among patients with eosinophilic asthma characteristics.
Conclusion
In conclusion, the use of benralizumab in the treatment of severe eosinophilic asthma appears to offer a promising new approach, allowing patients to significantly reduce their daily maintenance inhaled corticosteroid dose while maintaining asthma control. Further research is needed to continue exploring and refining these treatment strategies, but these studies offer hope to patients with severe eosinophilic asthma for improved management approaches and better quality of life.
